Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28865459 | 0.83 | KCNH2 (0.42) | — | |
| SCHEMBL27182260 | 0.83 | CYP19A1 (0.50) | MAPTALDH1A1RECQLLMNANPC1 | |
| SCHEMBL132013 | 0.81 | KCNH2 (0.49) | — | |
| SCHEMBL9003739 | 0.81 | SMN1; SMN2 (0.54) | MAPTALDH1A1GAALMNANPC1 | |
| SCHEMBL9837023 | 0.79 | MAPT (0.58) | MAPTALDH1A1GAALMNAMEN1 | |
| SCHEMBL3978868 | 0.75 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL9863084 | 0.75 | MAPK1 (0.45) | MAPTALDH1A1LMNAGSK3BPOLB | |
| SCHEMBL6351039 | 0.75 | MAPT (0.59) | MAPTALDH1A1GAAMMP2LMNA | |
| SCHEMBL9835773 | 0.75 | MAPT (0.46) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL14875009 | 0.74 | G6PD (0.49) | MAPTALDH1A1RECQLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-1802593-B1 | POLYMER-FILLER COUPLING ADDITIVES | BRIDGESTONE CORP (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-1802593-A2 | POLYMER-FILLER COUPLING ADDITIVES | Bridgestone Corporation (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006045088-A2 | POLYMER-FILLER COUPLING ADDITIVES | BRIDGESTONE CORPORATION (JP) | 2006-04-27 | — | — | WO | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | NOTUM 1547/4885MAPT 3263/4885ALDH1A1 1376/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | NOTUM 2546/4885MAPT 94/4885ALDH1A1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.